Table 1. Baseline Characteristics.
| Fluvoxamine (n = 80) | Placebo (n = 72) | |
|---|---|---|
| Age, median (IQR) [range], y | 46 (35-58) [20-75] | 45 (36-54) [21-69] |
| Sex at birth, No. (%) | ||
| Female | 56 (70) | 53 (74) |
| Male | 24 (30) | 19 (26) |
| Race, No. (%)a | ||
| White | 56 (70) | 50 (69) |
| Black | 18 (23) | 20 (28) |
| Asian | 3 (4) | 1 (1) |
| Other | 2 (3) | 1 (1) |
| Unknown | 1 (1) | 0 |
| American Indian/Alaska Native | 0 | 1 (1) |
| Ethnicity, No. (%)a | ||
| Non-Hispanic/Non-Latino | 75 (94) | 66 (92) |
| Hispanic/Latino | 3 (4) | 2 (3) |
| Unknown/not reported | 2 (3) | 4 (5) |
| Coexisting conditions, No. (%)a | ||
| Asthma | 17 (21) | 9 (13) |
| Hypertension | 15 (19) | 15 (21) |
| Diabetes | 9 (11) | 8 (11) |
| High cholesterol | 7 (9) | 7 (10) |
| Hyperthyroidism | 6 (8) | 6 (8) |
| Anxiety | 5 (6) | 1 (1) |
| Arthritisb | 4 (5) | 3 (4) |
| Depression | 1 (1) | 4 (6) |
| Body mass index category, No. (%)c | ||
| Underweight (<18.5) | 1 (1) | 1 (1) |
| Normal (18.5-24.9) | 14 (18) | 7 (10) |
| Overweight (25-29.9) | 22 (28) | 22 (31) |
| Obese (≥30) | 43 (54) | 42 (58) |
| Duration of COVID-19 symptoms, median (IQR) [range], da | 4 (3-5) [1-7] | 4 (3-5) [1-7] |
| Oxygen saturation, median (IQR) [range], % | 97 (96-98) [93-99] | 97 (96-98) [92-99] |
| Most severe COVID-19 symptom at baseline, No. (%)a | ||
| Loss of sense of smell | 26 (33) | 18 (25) |
| Fatigue | 17 (21) | 18 (25) |
| Body aches | 9 (11) | 13 (18) |
| Cough | 9 (11) | 1 (1) |
| Subjective fever | 8 (10) | 4 (6) |
| Loss of appetite | 3 (4) | 8 (11) |
| Chills | 3 (4) | 6 (8) |
| Shortness of breath | 2 (3) | 1 (1) |
| Loss of taste | 2 (3) | 2 (3) |
| Nausea | 1 (1) | 1 (1) |
Abbreviations: COVID-19, coronavirus disease 2019; IQR, interquartile range.
a
Per participant self-report.
b
Osteoarthritis or rheumatoid arthritis.
c
Calculated as weight in kilograms divided by height in meters squared.